Beam Therapeutics (NASDAQ:BEAM) announced on Tuesday that it received U.S. FDA's orphan drug designation for its cell therapy ...

Sickle cell disease is a genetic blood disorder caused by a single mutation in both copies of a gene coding for beta-globin. Beta-globin forms half of the oxygen-carrying molecule hemoglobin. This ...

Sickle cell disease is a genetic blood disorder caused by a single mutation in both copies of a gene coding for beta-globin. Beta-globin forms half of the oxygen-carrying molecule hemoglobin.

Sickle cell disease is a genetic blood disorder caused by a single mutation in both copies of a gene coding for beta-globin. Beta-globin forms half of the oxygen-carrying molecule hemoglobin.

The Pediatric Emergency Medicine and Pediatric Hematology/Oncology divisions at MUSC have joined forces to create and test an ...

Today is World Sickle Cell Disease Day. The international awareness day is observed annually to increase public knowledge and an understanding of sickle cell disease and the challenges experienced ...

Rates of vaso-occlusive crises were similar with crizanlizumab and placebo among patients with sickle cell disease. Results were at odds with the SUSTAIN trial, which showed a reduction in the ...

Sickle cell disease (SCD) is an inherited disorder that affects over 100,000 people in the United States, according to the Sickle Cell Disease Association of America, of that number, the Centers ...

Sickle cell conditions are genetic blood disorders that affect haemoglobin, the molecule in red blood cells responsible for carrying oxygen throughout the body. While both sickle cell trait and ...

Beam Therapeutics' investigational modified cell therapy for treating sickle-cell disease has been granted orphan-drug status by the Food and Drug Administration.